Chamber and committees

NHS Boards received notification on the 11 August of their share of the £50 million investment which has been allocated in its entirety to support NHS Health Boards to improve A&E waits through a new National Collaborative for Urgent and Unscheduled Care.

Each board’s share of the £50 million fund is listed below:

Three Rapid Cancer Diagnostic Services (RCDS), formerly known as Early Cancer Diagnostic Centres (ECDC), have been established in NHS Scotland, and we are committed to ensuring equitable access across the country.

RCDS’s provide primary care with a new referral route for patients with non-specific symptoms suspicious of cancer (i.e. weight loss, fatigue, nausea), which can often be a sign of blood cancer. The Clinical Leads for two of the Services are Haematologists, reflecting the role that this new model can play in diagnosing blood cancers earlier.

Our NHS Recovery Plan commits to providing greater public awareness of signs and symptoms of cancer, with a new national campaign in development and website being re-designed.

The Scottish Government will continue to work closely with primary care clinicians, including the Scottish Primary Care Cancer Group, to identify possible symptoms as early as possible and support appropriate referral via the Scottish Referral Guidelines for Suspected Cancer.

Scottish Government officials are meeting with NHS Education Scotland on 27 September to explore primary care cancer education. This follows the recent cessation of Cancer Research UK’s Clinical Engagement Team that played a key role in delivering cancer education across NHS Scotland in recent years.

The questions used in the next Scottish Cancer Patient Experience Survey will be relevant to all cancer patients including those with blood cancer. The data collected will be broken down by cancer type and published as it has been in previous years.

Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.

Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

The Scottish Stroke Improvement Programme (SSIP) Lead conducts a review process and meets with all NHS boards to understand the provision of stroke services and create a local action plan to improve performance where needed.

We recognise that the Scottish Stroke Care Standards are challenging for the service and expect Stroke Managed Clinical Networks and Health Boards to work together to drive forward quality improvement programmes of work to achieve these.

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

As part of the Scottish Medicines Consortium’s (SMC) continuing role in the UK-wide multi-agency RAPID C-19 initiative, the collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE) will extend to the multiple technology assessment (MTA) of the range of therapeutics for the treatment of COVID-19; therefore, a separate assessment of these medicines by the SMC will not be required.

My intention is to update Parliament with our Winter Resilience plans and publish our Winter Resilience Overview, covering both the NHS and Social Care, early next month, subject to discussions at Parliamentary Bureau. Caroline Lamb, CEO of NHS Scotland has also already written to NHS Boards and Integration Authorities regarding winter resilience plans at a national level and setting out clear expectations for local resilience and response.